<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01497470</url>
  </required_header>
  <id_info>
    <org_study_id>TV1011-DDI-105</org_study_id>
    <nct_id>NCT01497470</nct_id>
  </id_info>
  <brief_title>A Clinical Study in Cancer Patients to Investigate the Potential Impact of Custirsen, on the Blood Levels of the Chemotherapeutic Drug, Paclitaxel, When Given Together as Part of a Treatment Regimen</brief_title>
  <official_title>An Open-Label, One-Arm, One-Sequence Crossover Drug-Drug Interaction Study in Advanced Solid Tumor Subjects Subjects to Evaluate the Potential Effect of Custirsen (OGX-011) on the Pharmacokinetics of Paclitaxel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Achieve Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Achieve Life Sciences</source>
  <brief_summary>
    <textblock>
      The primary goal of this study is to determine if custirsen has an effect on the way the body
      distributes and gets rid of paclitaxel, the standard administered chemotherapy. The study
      will also evaluate if custirsen influences the way the body distributes and gets rid of
      carboplatin (another standard administered chemotherapy) and will measure custirsen blood
      levels in this cancer population. Finally, the study will evaluate the safety and
      tolerability of adding custirsen to the standard paclitaxel/carboplatin chemotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the impact of custirsen on paclitaxel pharmacokinetics</measure>
    <time_frame>0, 1, 2, 3, 3.25, 3.67, 4.5, 6, 8, 12, 24 and 48 hours after the start of paclitaxel infusion</time_frame>
    <description>The maximum peak concentration of paclitaxel after administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and tolerability of adding custirsen to standard paclitaxel/carboplatin chemotherapy</measure>
    <time_frame>0, 1, 2, 3, 3.25, 3.67, 4.5, 6, 8, 12, 24 and 48 hours after the start of paclitaxel infusion</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Paclitaxel/carboplatin with custirsen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Custirsen added to standard paclitaxel/carboplatin chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Custirsen, paclitaxel and carboplatin</intervention_name>
    <description>Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle</description>
    <arm_group_label>Paclitaxel/carboplatin with custirsen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of a solid tumor that is refractory to standard therapies and is
             not amenable to treatment with established curative or palliative therapies and for
             whom paclitaxel and carboplatin is deemed an acceptable treatment by the investigator

          -  Males or females ≥18 years of age

          -  Life expectancy of ≥12 weeks

          -  Minimum of 1 lesion

          -  ECOG performance status of 0, 1 or 2

          -  Adequate bone marrow reserve

          -  Adequate renal and liver function

        Exclusion Criteria:

          -  Brain metastases that are symptomatic or require ongoing treatment

          -  Major trauma or surgery within last 2 months, acute infection within 2 weeks (14
             days), or radiotherapy, chemotherapy, immunotherapy or hormonal therapy within past 4
             weeks

          -  Persistent grade 2 or greater toxicity related to prior therapy

          -  Grade 2 or greater peripheral neuropathy

          -  Recent or current use of Cyp3A4, Cyp2C8 or P-gp inhibitors

          -  Recent or current use of CYP enzyme inducers
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Teva Investigational Site 002</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 001</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 003</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 004</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2011</study_first_submitted>
  <study_first_submitted_qc>December 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2011</study_first_posted>
  <last_update_submitted>October 7, 2016</last_update_submitted>
  <last_update_submitted_qc>October 7, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>paclitaxel</keyword>
  <keyword>carboplatin</keyword>
  <keyword>custirsen</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cancer</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

